AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases

 AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases

AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases

Shots:

  • The collaboration will extend in 2022 for an additional 3yrs. Calico will lead R&D until 2025 & will advance projects into P-IIa through 2030 while AbbVie will support Calico in its early R&D efforts, following the completion of P-IIa studies, will get the option to manage late-stage development & commercial activities
  • Both the companies will equally share costs & profits and each of them will contribute $500M to the collaboration. This marks the second extension of the collaboration originally established in 2014
  • Since 2014, the collaboration has produced 20+ early-stage programs addressing disease across I-O and neurodegeneration and has yielded new insights into the biology of aging

Click here to­ read full press release/ article | Ref: Abbvie | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post